Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. (Q54607194)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. |
scientific article |
Statements
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. (English)
M H G Langenberg
P O Witteveen
J Roodhart
M P Lolkema
H M W Verheul
M Mergui-Roelvink
E Brendel
J Krätzschmar
B Loembé
A Nol-Boekel
O Christensen
J H M Schellens
E E Voest
4 March 2011
22
11
2508-2515